Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
Abstract Observational studies have suggested that HER2 inhibition with trastuzumab may be associated with an increased incidence of intracranial metastatic disease (IMD) due to its ability to prolong survival. We hypothesized that prolonged survival associated with dual-agent HER2 inhibition may be...
Guardado en:
Autores principales: | Anders Wilder Erickson, Steven Habbous, Christianne Hoey, Katarzyna J. Jerzak, Sunit Das |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fbb56a6898a446b5a5e73ebedbd73af9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Laura Pizzuti, et al.
Publicado: (2021) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Fara Brasó-Maristany, et al.
Publicado: (2020) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021) -
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
por: Abdel Kader Y, et al.
Publicado: (2013)